Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.
作者： F. Cappuzzo , E. Magrini , G. L. Ceresoli , S. Bartolini , E. Rossi
DOI: 10.1093/JNCI/DJH217
关键词:
摘要: … patients may respond to gefitinib therapy, we evaluated the … gefitinib therapy and evaluated their response to gefitinib … of Akt and of MAPK and gefitinib activity in terms of response …
oup.com
unipg.it
oxfordjournals.org
paperity.org
core.ac.uk 参考文章(56)
William J. Gullick, David S. Salomon, The erbB family of receptors and their ligands: multiple targets for therapy. Addis International. ,(2001)
Mark L. Levitt, Patrick P. Koty, Tyrosine kinase inhibitors in preclinical development. Investigational New Drugs. ,vol. 17, pp. 213- 226 ,(1999) , 10.1023/A:1006372102543
G. H. Sato, J. Mendelsohn, J. Polikoff, J. D. Sato, A. D. Le, T. Kawamoto, Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Molecular biology & medicine. ,vol. 1, pp. 511- 529 ,(1983)
LH Sobin, WD Travis, TV Colby, B Corrin, Y Shimosato, E Brambilla, Histological Typing of Lung and Pleural Tumours ,(1999)
Timothy S. Lewis, Paul S. Shapiro, Natalie G. Ahn, Signal Transduction through MAP Kinase Cascades Advances in Cancer Research. ,vol. 74, pp. 49- 139 ,(1998) , 10.1016/S0065-230X(08)60765-4
David W. Hedley, Sylvia S. W. Ng, Ming-Sound Tsao, Sue Chow, Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Research. ,vol. 60, pp. 5451- 5455 ,(2000)
David R. Cox, Regression Models and Life-Tables Springer Series in Statistics. ,vol. 34, pp. 527- 541 ,(1992) , 10.1007/978-1-4612-4380-9_37
Mark M. Moasser, Steven D. Averbuch, Neal Rosen, Andrea Basso, The Tyrosine Kinase Inhibitor ZD1839 ("Iressa") Inhibits HER2-driven Signaling and Suppresses the Growth of HER2-overexpressing Tumor Cells Cancer Research. ,vol. 61, pp. 7184- 7188 ,(2001)
Mark G. Kris, Howard I. Scher, Vincent A. Miller, Maureen F. Zakowski, Francis M. Sirotnak, Efficacy of Cytotoxic Agents against Human Tumor Xenografts Is Markedly Enhanced By Coadministration of ZD1839 (Iressa), an Inhibitor of EGFR Tyrosine Kinase Clinical Cancer Research. ,vol. 6, pp. 4885- 4892 ,(2000)
David Solit, Mark M. Moasser, Qing-Bai She, Andrea Basso, Resistance to Gefitinib in PTEN-Null HER-Overexpressing Tumor Cells Can Be Overcome through Restoration of PTEN Function or Pharmacologic Modulation of Constitutive Phosphatidylinositol 3′-Kinase/Akt Pathway Signaling Clinical Cancer Research. ,vol. 9, pp. 4340- 4346 ,(2003)